Table 2.
Comparison of patients taking nirmatrelvir-ritonavir and molnupiravir.
| Characteristics | Nirmatrelvir-ritonavir (n = 93) | Molnupiravir (n = 57) | P value |
|---|---|---|---|
| Age, yr | 61.0 (53.0–72.0) | 66.0 (56.0–77.0) | .13* |
| Sex | |||
| Male | 42 (45.2) | 27 (47.4) | .87† |
| Female | 51 (54.8) | 30 (52.6) | |
| Vaccination status | |||
| No vaccination | 7 (7.5) | 8 (14.0) | .41† |
| 1 or 2 doses | 8 (8.6) | 10 (17.5) | |
| ≥3 doses | 78 (83.9) | 39 (68.4) | |
| D from symptom onset to antiviral therapy | 2.0 (1.0–2.0) | 2.0 (1.0–2.0) | .37* |
| D from last vaccination until diagnosis | 260 (176–321) | 268 (179–333) | .43* |
| Cycle threshold of PCR at diagnosis | 20.3 (17.0–25.0) | 18.5 (16.3–22.4) | .25* |
| COVID-19 history | 4 (4.3) | 2 (3.5) | .99† |
| Comorbidities | |||
| Obesity (BMI > 25) | 28 (30.1) | 13 (22.8) | .35† |
| Hypertension | 42 (45.2) | 26 (45.6) | .99† |
| Diabetes mellitus | 19 (20.4) | 21 (36.8) | .04† |
| Dyslipidemia | 41 (44.1) | 17 (29.8) | .09† |
| Cardiovascular disease | 12 (12.9) | 11 (19.3) | .35† |
| Chronic kidney disease | 4 (4.3) | 14 (24.6) | <.01† |
| Chronic pulmonary disease | 4 (4.3) | 8 (14.0) | .06† |
| Liver cirrhosis | 4 (4.3) | 5 (8.8) | .30† |
| Stroke | 2 (2.2) | 5 (5.0) | .11† |
| Rheumatic disease | 5 (5.4) | 4 (7.0) | .73† |
| Malignant tumor | 20 (21.5) | 14 (24.6) | .69† |
| Hematologic malignancy | 6 (6.5) | 6 (10.5) | .37† |
| Organ transplant recipient | 0 (0.0) | 19 (33.3) | <.01† |
| Symptom score | |||
| D 0 | 4.0 (3.0–5.0) | 4.0 (2.0–6.0) | .82* |
| D 7 | 1.0 (0.0–2.0) | 1.0 (0.0–2.0) | .51* |
| D 14 | 1.0 (0.0–2.0) | 1.0 (0.0–2.0) | .10* |
| D 28 | 0.0 (0.0–1.0) | 0.0 (0.0–1.0) | .64* |
Data are presented as median (interquartile range) or number (%).
BMI = body mass index, COVID-19 = coronavirus disease 2019, PCR = polymerase chain reaction.
*
P value from Student t test or Mann–Whitney U test.
†
P value from Chi-square (χ2) test or Fisher exact test.